Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical Misses on Revenue, Stock Down 0.69%

Collegium Pharmaceutical reported a loss per share that was better than expected, which indicates some level of operational efficiency. However, the lack of revenue data and no guidance update may raise concerns among investors. The stock reacted negatively, declining by 0.69%, reflecting uncertainty about the company's future performance.